Clostridium difficile infections in a Canadian Tertiary Care Hospital before and during a regional epidemic associated with the BI/NAP1/027 strain

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 9, 2008, Pages 3180-3187

  Labbé, Annie Claude ^a,b   Poirier, Louise ^a,b   MacCannell, Duncan ^c   Louie, Thomas ^c   Savoie, Michel ^a   Béliveau, Claire ^a,b   Laverdière, Michel ^a,b   Pépin, Jacques ^d  

^a MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIUM ISOLATE; CANADA; CLOSTRIDIUM DIFFICILE; COMORBIDITY; CONTROLLED STUDY; ENDEMIC DISEASE; EPIDEMIC; EXPOSURE; HOSPITAL; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; IN VITRO STUDY; MORBIDITY; MORTALITY; MULTIVARIATE ANALYSIS; NONHUMAN; PRIORITY JOURNAL; TERTIARY HEALTH CARE;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; DISEASE OUTBREAKS; DRUG RESISTANCE, BACTERIAL; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; HOSPITALIZATION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROGNOSIS; QUEBEC; RIBOTYPING; RISK FACTORS;

EID: 50949130251     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00146-08     Document Type: Article

References (37)

1. Adams, D. A., M. M. Riggs, and C. J. Donskey. 2007. Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic Clostridium difficile strains in the cecal contents of mice. Antimicrob. Agents Chemother. 51:2674-2678.
2. Aspevall, O., A. Lundberg, L. G. Burman, T. Akerlund, and B. Svenungsson. 2006. Antimicrobial susceptibility pattern of Clostridium difficile and its relation to PCR ribotypes in a Swedish university hospital. Antimicrob. Agents Chemother. 50:1890-1892.
3. Barbut, F., P. Mastrantonio, M. Delmee, J. Brazier, E. Kuijper, and I. Poxton. 2007. Prospective study of Clostridium difficile infections in Europe with phenotypic and genotypic characterisation of the isolates. Clin. Microbiol. Infect. 13:1048-1057.
4. Bolton, R. P., and M. A. Culshaw. 1986. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 27:1169-1172.
5. Charlson, M., T. P. Szatrowski, J. Peterson, and J. Gold. 1994. Validation of a combined comorbidity index. J. Clin. Epidemiol. 47:1245-1251.
6. Comité sur les Infections Nosocomiales du Québec. 2005. Prévention et contrôle de la diarrhée nosocomiale associée au Clostridium difficile au Québec - lignes directrices pour les établissements de soins, 3e éd., février 2005. http://www.inspq.qc.ca/pdf/publications/362-CDifficile- LignesDirectrices -3eEdition.pdf. Accessed 30 April 2007.
7. Dubberke, E. R., K. A. Reske, M. A. Olsen, K. M. McMullen, J. L. Mayfield, L. C. McDonald, and V. J. Fraser. 2007. Evaluation of Clostridium difficile-associated disease pressure as a risk factor for C. difficile-associated disease. Arch. Intern. Med. 167:1092-1097.
8. Dubberke, E. R., K. A. Reske, Y. Yan, M. A. Olsen, L. C. McDonald, and V. J. Fraser. 2007. Clostridium difficile-associated disease in a setting of endemicity: identification of novel risk factors. Clin. Infect. Dis. 45:1543-1549.
9. Goorhuis, A., T. van der Kooi, N. Vaessen, F. W. Dekker, R. Van den Berg, C. Harmanus, S. van den Hof, D. W. Notermans, and E. J. Kuijper. 2007. Spread and epidemiology of Clostridium difficile polymerase chain reaction ribotype 027/toxinotype III in The Netherlands. Clin. Infect. Dis. 45:695-703.
10. Guilbault, C., A. C. Labbe, L. Poirier, L. Busque, C. Beliveau, and M. Laverdiere. 2002. Development and evaluation of a PCR method for detection of the Clostridium difficile toxin B gene in stool specimens. J. Clin. Microbiol. 40:2288-2290.
11. Health Protection Agency. 2006. Mandatory surveillance of healthcare associated infections report, 2006. http://www.hpa.org.uk/infections/ topics_az/hai/mandatory_report_2006.htm. Accessed 25 November 2006.
12. Hubert, B., V. G. Loo, A. M. Bourgault, L. Poirier, A. Daseal, E. Fortin, M. Dionne, and M. Lorange. 2007. A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile-associated disease in Quebec. Clin. Infect. Dis. 44:238-244.
13. Institut National de Santé Publique du Québec. 2005. Surveillance des diarrhées associées à Clostridium difficile au Québec - résultats préliminaires du 22 août au 13 Novembre 2004. http://www.inspq.qc.ca/publications/notice.asp? E=p&NumPublication=350. Accessed 15 December 2007.
14. Institut National de Santé Publique du Québec. 2006. La situation démographique au Québec. Bilan 2006. Institut de Statistique du Québec, http: //www.stat.gouv.qc.ca/publications/demograp/ pdf2006/Bilan2006c4.pdf. Accessed 15 December 2007.
15. Joseph, R., D. Demeyer, D. Vanrenterghem, R. van den Berg, E. Kuijper, and M. Delmee. 2005. First isolation of Clostridium difficile PCR ribotype 027, toxinotype III in Belgium. Euro. Surveill. 10:E051020.
16. Kuijper, E. J., B. Coignard, J. S. Brazier, C. Suetens, D. Drudy, C. Wiuff, H. Pituch, P. Reichert, F. Schneider, A. F. Widmer, K. E. Olsen, F. Allerberger, D. W. Notermans, F. Barbut, M. Delmee, M. Wilcox, A. Pearson, B. C. Patel, D. J. Brown, R. Frei, T. Akerlund, I. R. Poxton, and P. Tull. 2007. Update of Clostridium difficile-associated disease due to PCR ribotype 027 in Europe. Euro. Surveill. 12:E1-E2.
17. Kuijper, E. J., R. J. van den Berg, S. Debast, C. E. Visser, D. Veenendaal, A. Troelstra, T. van der Kooi, S. van den Hof, and D. W. Notermans. 2006. Clostridium difficile ribotype 027, toxinotype III, The Netherlands. Emerg. Infect. Dis. 12:827-830.
18. Loo, V. G., L. Poirier, M. A. Miller, M. Oughton, M. D. Libman, S. Michaud, A. M. Bourgault, T. Nguyen, C. Frenette, M. Kelly, A. Vibien, P. Brassard, S. Fenn, K. Dewar, T. J. Hudson, R. Horn, P. Rene, Y. Monczak, and A. Daseal. 2005. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N. Engl. J. Med. 353:2442-2449.
19. MacCannell, D. R., T. J. Louie, D. B. Gregson, M. Laverdiere, A. C. Labbe, F. Laing, and S. Henwick. 2006. Molecular analysis of Clostridium difficile PCR ribotype 027 isolates from eastern and western Canada. J. Clin. Microbiol. 44:2147-2152.
20. Matamouros, S., P. England, and B. Dupuy. 2007. Clostridium difficile toxin expression is inhibited by the novel regulator TcdC. Mol. Microbiol. 64: 1274-1288.
21. McDonald, L. C. 2007. Confronting Clostridium difficile in inpatient health care facilities. Clin. Infect. Dis. 45:1274-1276.
22. McDonald, L. C, G. E. Killgore, A. Thompson, R. C. Owens, Jr., S. V. Kazakova, S. P. Sambol, S. Johnson, and D. N. Gerding. 2005. An epidemic, toxin gene-variant strain of Clostridium difficile. N. Engl. J. Med. 353:2433-2441.
23. McDonald, L. C., M. Owings, and D. B. Jernigan. 2006. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg. Infect. Dis. 12:409-415.
24. Musher, D. M., N. Logan, R. J. Hamill, H. L. Dupont, A. Lentnek, A. Gupta, and J. F. Rossignol. 2006. Nitazoxanide for the treatment of Clostridium difficile colitis. Clin. Infect. Dis. 43:421-427.
25. Muto, C. A., M. K. Blank, J. W. Marsh, E. N. Vergis, M. M. O'Leary, K. A. Shutt, A. W. Pasculle, M. Pokrywka, J. G. Garcia, K. Posey, T. L. Roberts, B. A. Potoski, G. E. Blank, R. L. Simmons, P. Veldkamp, L. H. Harrison, and D. L. Paterson. 2007. Control of an outbreak of infection with the hypervirulent Clostridium difficile BI strain in a university hospital using a comprehensive "bundle" approach. Clin. Infect. Dis. 45:1266-1273.
26. Muto, C. A., M. Pokrywka, K. Shutt, A. B. Mendelsohn, K. Nouri, K. Posey, T. Roberts, K. Croyle, S. Krystofiak, S. Patel-Brown, A. W. Pasculle, D. L. Paterson, M. Saul, and L. H. Harrison. 2005. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect. Control Hosp. Epidemiol. 26:273-280.
27. National Committee for Clinical Laboratory Standards. 2004. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard, 6th ed. NCCLS document M11-A6, Vol. 24, No. 2. National Committee for Clinical Laboratory Standards, Wayne, PA.
28. Owens, R. C., Jr., C. J. Donskey, R. Gaynes, V. G. Loo, and C. A. Muto. 2008. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin. Infect. Dis. 46(Suppl. 1):S19-S31.
29. Pepin, J., N. Saheb, M. A. Coulombe, M. E. Alary, M. P. Corriveau, S. Authier, M. Leblanc, G. Rivard, M. Bettez, V. Primeau, M. Nguyen, C. E. Jacob, and L. Lanthier. 2005. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin. Infect. Dis. 41:1254-1260.
30. Pepin, J., L. Valiquette, and B. Cossette. 2005. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 173:1037-1042.
31. Razavi, B., A. Apisarnthanarak, and L. M. Mundy. 2007. Clostridium difficile: emergence of hypervirulence and fluoroquinolone resistance. Infection 35:300-307.
32. Redelings, M. D., F. Sorvillo, and L. Mascola. 2007. Increase in Clostridium difficile-related mortality, United States, 1999-2004. Emerg. Infect. Dis. 13:1417-1419.
33. Ricciardi, R., D. A. Rothenberger, R. D. Madoff, and N. N. Baxter. 2007. Increasing prevalence and severity of Clostridium difficile colitis in hospitalized patients in the United States. Arch. Surg. 142:624-631.
34. Smith, A. 2005. Outbreak of Clostridium difficile infection in an English hospital linked to hypertoxin-producing strains in Canada and the US. Euro. Surveill. 10:E050630.
35. Valiquette, L., B. Cossette, M. P. Garant, H. Diab, and J. Pepin. 2007. Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficile-associated disease caused by the hypervirulent NAP1/027 strain. Clin. Infect. Dis. 45(Suppl. 2):S112-S121.
36. Warny, M., J. Pepin, A. Fang, G. Killgore, A. Thompson, J. Brazier, E. Frost, and L. C. McDonald. 2005. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366:1079-1084.
37. WHO Collaborating Centre for Drug Statistics Methodology. 2007. ATC/DDD index 2007. WHO Collaborating Centre for Drug Statistics Methodology. http://www.whocc.no/atcddd/. Accessed 23 April 2007.